PL367040A1 - Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor - Google Patents

Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor

Info

Publication number
PL367040A1
PL367040A1 PL02367040A PL36704002A PL367040A1 PL 367040 A1 PL367040 A1 PL 367040A1 PL 02367040 A PL02367040 A PL 02367040A PL 36704002 A PL36704002 A PL 36704002A PL 367040 A1 PL367040 A1 PL 367040A1
Authority
PL
Poland
Prior art keywords
adrenoceptor
alpha
prevention
treatment
compounds useful
Prior art date
Application number
PL02367040A
Other languages
Polish (pl)
Inventor
Topi Joutsamo
Andrei Yurievitch Tauber
Harri Salo
Anna-Marja Hoffren
Siegfried Wurster
Original Assignee
Oy Juvantia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20011560A external-priority patent/FI116940B/en
Application filed by Oy Juvantia Pharma Ltd filed Critical Oy Juvantia Pharma Ltd
Publication of PL367040A1 publication Critical patent/PL367040A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL02367040A 2001-07-20 2002-07-22 Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor PL367040A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30644901P 2001-07-20 2001-07-20
FI20011560A FI116940B (en) 2001-07-20 2001-07-20 New N-pyrimidinyl para-aminobenzenesulfonamide derivatives as Alpha-2B adrenoceptor antagonists, useful for treating e.g. coronary heart disease, myocardial infarction, angina, restenosis and hypertension

Publications (1)

Publication Number Publication Date
PL367040A1 true PL367040A1 (en) 2005-02-21

Family

ID=26161203

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02367040A PL367040A1 (en) 2001-07-20 2002-07-22 Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor

Country Status (10)

Country Link
EP (1) EP1417182A1 (en)
JP (1) JP2004535467A (en)
CA (1) CA2454187A1 (en)
HU (1) HUP0401076A2 (en)
IL (1) IL159511A0 (en)
MX (1) MXPA04000615A (en)
NZ (1) NZ530366A (en)
PL (1) PL367040A1 (en)
RU (1) RU2004105035A (en)
WO (1) WO2003008387A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI118265B (en) * 2004-01-15 2007-09-14 Jurilab Ltd Oy A method for detecting the risk of acute myocardial infarction and coronary heart disease
WO2006100263A2 (en) 2005-03-23 2006-09-28 Klat Pharma Animal Health Gmbh Use of amides of sulfadimidine for the treatment of intestinal diseases in veterinary science
EA202091020A1 (en) 2017-10-24 2020-07-24 Байер Акциенгезельшафт SUBSTITUTED IMIDAZOPYRIDINAMIDES AND THEIR APPLICATION
WO2020216669A1 (en) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenyl-substituted imidazopyridine amides and use thereof
CN116396236A (en) * 2023-04-19 2023-07-07 河北科技大学 Diaryl methyl sulfonamide compound and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (en) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents
NZ520500A (en) * 2000-02-11 2005-01-28 Juvantia Pharma Ltd Oy Sulfonamides useful for the treatment or prevention of a disease i.e. vascular and coronary heart disease mediated by the alpha-2B-adrenoceptor
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators

Also Published As

Publication number Publication date
RU2004105035A (en) 2005-06-27
WO2003008387A1 (en) 2003-01-30
HUP0401076A2 (en) 2004-09-28
NZ530366A (en) 2005-02-25
JP2004535467A (en) 2004-11-25
MXPA04000615A (en) 2004-04-20
IL159511A0 (en) 2004-06-01
CA2454187A1 (en) 2003-01-30
EP1417182A1 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL144101A0 (en) Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin d2
AU2001282873A1 (en) Quinuclidine-substituted aryl compounds for treatment of disease
EP1594512A4 (en) Compounds for the treatment of viral infection
ZA200305691B (en) The use of substituted azetidione compounds for the treatment of sitosterolemia
EP1390029A4 (en) Phenylindoles for the treatment of hiv
IL161070A0 (en) Compositions for the treatment of infectious diseases
AU2001284645A1 (en) Quinuclidine-substituted aryl compounds for treatment of disease
GB0329874D0 (en) Compounds useful for the treatment of diseases
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
EP1461030A4 (en) Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
PL369402A1 (en) Use for the treatment of gastroesophageal reflux disease
IL159511A0 (en) Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
AU2002364711A8 (en) Substituted 5-hydroxy-indole compounds for the treatment of glaucoma
FI20011560A (en) Compounds Useful for the Treatment or Prevention of Alpha-2B Adrenoceptor Mediated Disease
GB2392838B (en) Calcium L-threonate for preventing or treating cartilage related diseases
ZA200205835B (en) Compounds useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor.
IL151017A0 (en) Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
GB0100092D0 (en) Treatment of degenerative diseases
MXPA03006468A (en) Compositions for prevention or treatment of hepatopathy.
HUP0400020A2 (en) Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
AU2002359282A1 (en) Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
PL354698A1 (en) Pharmaceutical compound for prevention or treatment of self-immunization based diseases

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)